<DOC>
	<DOCNO>NCT00242216</DOCNO>
	<brief_summary>Atazanavir ( ATV ) fosamprenavir ( fAPV ) new protease inhibitor administer once-a-day boosted ritonavir ( r ) . Prior study demonstrate effective treatment ARV-naïve HIV-infected people . This study design demonstrate HAART regimen contain ATV/r inferior HAART regimen contain fAPV/r , ARV-naïve patient 96-week period . This phase IV , single center , randomize , open label , 2-arm clinical trial ARV therapy-naïve patient HIV-1 RNA &gt; 1,000 copes/mL CD4 cell count &lt; 350 cells/mm3 . Patients randomize receive tenofovir emtricitabine plus either ATV ( 300mg qd ) ritonavir ( 100mg qd ) fAPV ( 1400mg qd ) ritonavir ( 200mg qd ) .</brief_summary>
	<brief_title>`` The Once A Day Protease Inhibitor Regimens ''</brief_title>
	<detailed_description>Over past decade , significant advance toward fight progression HIV disease . Current treatment strategy consist utilization potent combination antiretroviral therapy suppress HIV replication detectable limit limit potential emergence resistant virus , boost CD4 cell count thereby delay disease progression . Treatment HIV-1 infection Highly Active Antiretroviral Therapy ( HAART ) regimens contain protease inhibitor ( PI ) two nucleoside reverse transcriptase inhibitor ( NRTIs ) show prolong survival decrease disease progression . Despite potent antiretroviral agent , current available therapy continue fail patient . Poor adherence complex treatment regimens remain significant cause suboptimal viral suppression lead emerge resistant virus . Atazanavir fosamprenavir recently FDA approve protease inhibitor . The efficacy safety profile two drug establish clinical trial enrol antiretroviral therapy naïve protease inhibitor experience patient . Atazanavir fosamprenavir protease inhibitor approve day regimen may set new standard treatment antiretroviral therapy naïve HIV infect patient . Adherence medicine , key component treatment success , could significantly improve use daily regimen . However , head-to-head trial compare safety efficacy fosamprenavir atazanavir publish . This prospective , randomize , open label 2-arm study compare two protease inhibitor therapy antiretroviral treatment-naïve HIV-infected patient . Patients successfully screen eligibility randomize receive tenofovir emtricitabine plus either atazanavir ( 300mg qd ) ritonavir ( 100mg qd ) fosamprenavir ( 1400mg qd ) ritonavir ( 200mg qd ) . Participants undergo assessment day 1 attend study visit week 6 , 12 every 3 month completion study week 96 . `` Antiretroviral Medication Self-Report '' `` 3-Day HIV Medication Self-Report '' questionnaires apply week 6 , 12 every 3 month , thereafter , week 96 . `` Changes Body Appearance '' questionnaire apply baseline week 24 , 48 , 72 , 96 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>18 year age old . Patient agree participate study give write informed consent . Documentation HIV infection . No prior treatment antiretroviral agent . CD4 cell count &lt; 350 cell x mm3 AIDS defining condition . Viral load &gt; 1,000 copies/mL Less 18 year old . Current pregnancy breastfeeding . Any previous antiretroviral regimen . Severe hepatic impairment precludes use either study drug . This define laboratory value Grade 3 4 ACTG scale . Use contraindicate medication define package insert drug . Any condition , judgment investigator , preclude successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>HIV-1 infected people</keyword>
	<keyword>Antiretroviral treatment-naïve</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Fosamprenavir</keyword>
	<keyword>ARV Treatment Naive</keyword>
</DOC>